Table I.
Association between clinical and molecular response and miRNA-124, CDK4, CDK6 and EZH2 expression.
| Patient ID | Age, years | Gender | Diagnosis | Best response | miRNA-124 inductiona | CDK4 inhibitionb | CDK6 inhibitionb | EZH2 inhibitionc |
|---|---|---|---|---|---|---|---|---|
| 3 | 72 | F | MDS | CR | Yes | Yes | Yes | Yes |
| 7 | 58 | M | AML | Resistant | No | No | No | No |
| 8 | 75 | M | AML | Resistant | No | No | No | No |
| 18 | 67 | F | MDS | PR | No | Yes | Yes | Yes |
| 22 | 78 | M | AML | CR | Yes | No | No | No |
| 23 | 69 | F | AML | Resistant | No | No | No | Yes |
| 26 | 75 | M | MDS | PD | No | No | No | Yes |
| 28 | 69 | M | AML | PR | Yes | Yes | Yes | Yes |
| 33 | 62 | F | MDS | Marrow CR | Yes | Yes | Yes | Yes |
a
miRNA-124 2.0-fold or greater induction over screen.
b
CDK4, CDK6 1.0-fold or greater inhibition over screen.
c
EZH2 2.0-fold or greater inhibition over screen. miRNA, microRNA; CDK, cyclin-dependent kinase; EZH2, enhancer of zeste homolog 2.